One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents

Joseph M Coney,1 Jasmyne E McCoy,1 Samriddhi Buxy Sinha,2 Nina Sonbolian,2 Lujia Zhou,3 Thomas P Hull,1 Shawn A Lewis,1 David G Miller,1 Michael A Novak,1 Scott D Pendergast,1 Hang Pham,1 Sean M Platt,1 Llewelyn J Rao,1 Jerome P Schartman,1 Lawrence J Singerman,1 Richard Donkor,1 Margaret Fink,1 Rya...

Full description

Bibliographic Details
Main Authors: Coney JM, McCoy JE, Buxy Sinha S, Sonbolian N, Zhou L, Hull TP, Lewis SA, Miller DG, Novak MA, Pendergast SD, Pham H, Platt SM, Rao LJ, Schartman JP, Singerman LJ, Donkor R, Fink M, Zubricky R, Karcher H
Format: Article
Language:English
Published: Dove Medical Press 2023-11-01
Series:Clinical Ophthalmology
Subjects:
alternating anti-vegf treatments
brolucizumab
neovascular age-related macular degeneration
wet age-related macular degeneration
12-month outcomes
18-month outcomes
Online Access:https://www.dovepress.com/one-year-and-18-month-outcomes-in-namd-patient-eyes-switched-to-broluc-peer-reviewed-fulltext-article-OPTH

Internet

https://www.dovepress.com/one-year-and-18-month-outcomes-in-namd-patient-eyes-switched-to-broluc-peer-reviewed-fulltext-article-OPTH

Similar Items